167 related articles for article (PubMed ID: 30123267)
21. DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-κB activation.
Hu X; Liu S; Liu X; Zhang J; Liang Y; Li Y
Endocrine; 2017 Mar; 55(3):754-763. PubMed ID: 27612849
[TBL] [Abstract][Full Text] [Related]
22. Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK/Akt/mTOR signaling and autophagy.
Zhong J; Gong W; Lu L; Chen J; Lu Z; Li H; Liu W; Liu Y; Wang M; Hu R; Long H; Wei L
Int Immunopharmacol; 2017 Jan; 42():176-184. PubMed ID: 27919004
[TBL] [Abstract][Full Text] [Related]
23. Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms.
Alqahtani QH; Alshehri S; Alhusaini AM; Sarawi WS; Alqarni SS; Mohamed R; Kumar MN; Al-Saab J; Hasan IH
Diseases; 2023 Dec; 11(4):. PubMed ID: 38131990
[TBL] [Abstract][Full Text] [Related]
24.
Kim JH; Sim HA; Jung DY; Lim EY; Kim YT; Kim BJ; Jung MH
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569635
[No Abstract] [Full Text] [Related]
25. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
26. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
28. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.
Xiang M; Wang PX; Wang AB; Zhang XJ; Zhang Y; Zhang P; Mei FH; Chen MH; Li H
J Hepatol; 2016 Jun; 64(6):1365-77. PubMed ID: 26860405
[TBL] [Abstract][Full Text] [Related]
29. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA
Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664
[TBL] [Abstract][Full Text] [Related]
30. Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway.
Wang X; Ke J; Zhu YJ; Cao B; Yin RL; Wang Y; Wei LL; Zhang LJ; Yang LY; Zhao D
Cell Death Discov; 2021 Sep; 7(1):236. PubMed ID: 34493714
[TBL] [Abstract][Full Text] [Related]
31. Oral Administration of Apple Procyanidins Ameliorates Insulin Resistance via Suppression of Pro-Inflammatory Cytokine Expression in Liver of Diabetic ob/ob Mice.
Ogura K; Ogura M; Shoji T; Sato Y; Tahara Y; Yamano G; Sato H; Sugizaki K; Fujita N; Tatsuoka H; Usui R; Mukai E; Fujimoto S; Inagaki N; Nagashima K
J Agric Food Chem; 2016 Nov; 64(46):8857-8865. PubMed ID: 27792335
[TBL] [Abstract][Full Text] [Related]
32. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
Gault VA; Lennox R; Flatt PR
Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
[TBL] [Abstract][Full Text] [Related]
33. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
[TBL] [Abstract][Full Text] [Related]
34. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
[TBL] [Abstract][Full Text] [Related]
35. Diurnal Variation of Sitagliptin-Induced Pharmacological Effects in C57BL/6J Mice.
Yoshioka H; Hirose Y; Ohishi R; Tominaga S; Torii-Goto A; Park SJ; Miura N; Yoshikawa M
Biol Pharm Bull; 2019; 42(9):1562-1568. PubMed ID: 31474716
[TBL] [Abstract][Full Text] [Related]
36. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
[TBL] [Abstract][Full Text] [Related]
37. Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes.
Lim YM; Lim H; Hur KY; Quan W; Lee HY; Cheon H; Ryu D; Koo SH; Kim HL; Kim J; Komatsu M; Lee MS
Nat Commun; 2014 Sep; 5():4934. PubMed ID: 25255859
[TBL] [Abstract][Full Text] [Related]
38. Maresin 1 mitigates liver steatosis in ob/ob and diet-induced obese mice.
Laiglesia LM; Lorente-Cebrián S; Martínez-Fernández L; Sáinz N; Prieto-Hontoria PL; Burrell MA; Rodríguez-Ortigosa CM; Martínez JA; Moreno-Aliaga MJ
Int J Obes (Lond); 2018 Mar; 42(3):572-579. PubMed ID: 28895586
[TBL] [Abstract][Full Text] [Related]
39. Sitagliptin-mediated preservation of endothelial progenitor cell function via augmenting autophagy enhances ischaemic angiogenesis in diabetes.
Dai X; Zeng J; Yan X; Lin Q; Wang K; Chen J; Shen F; Gu X; Wang Y; Chen J; Pan K; Cai L; Wintergerst KA; Tan Y
J Cell Mol Med; 2018 Jan; 22(1):89-100. PubMed ID: 28799229
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.
Gao L; Wang PX; Zhang Y; Yu CJ; Ji Y; Wang X; Zhang P; Jiang X; Jin H; Huang Z; Zhang ZR; Li H
J Hepatol; 2016 Jul; 65(1):125-136. PubMed ID: 27032381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
